Man Group
ARQT icon

Man Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Man Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Buy
94,272
+30,053
+47% +$700K ﹤0.01% 1466
2026
Q1 		$1.51M Buy
64,219
+55,260
+617% +$1.41M ﹤0.01% 1678
2025
Q4 		$260K Buy
+8,959
New +$229K ﹤0.01% 2064
2023
Q3 		– Sell
-96,600
Closed -$921K – 1913
2023
Q2 		$921K Buy
+96,600
New +$1.07M ﹤0.01% 1411
2023
Q1 		– Hold
0
– – – 1406

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Man Group's ARQT Position: Q2 2026 in Review

Man Group increased its Arcutis Biotherapeutics (ARQT) stake by 47% in Q2 2026, buying an estimated $700K and bringing the position to 94,272 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

Man Group first reported a position in ARQT in Q2 2023 and has held it in 4 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Man Group held 94,272 shares of Arcutis Biotherapeutics worth $2.47M as of Q2 2026.
  • Man Group bought 30,053 Arcutis Biotherapeutics shares in Q2 2026, an estimated $700K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1466 holding.
  • Man Group first reported a position in Arcutis Biotherapeutics in Q2 2023 and has held it in 4 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.